Document:

Exhibit 10.49

 

Second Amendment to Amended and Restated Distribution Agreement

(REMODULIN®)

 

THIS SECOND AMENDMENT TO AMENDED AND RESTATED DISTRIBUTION AGREEMENT  (this “Second Amendment”) is made and effective November 1, 2016 (the “Second Amendment Effective Date”) by and among, United Therapeutics Corporation, a Delaware corporation having offices at 1040 Spring Street, Silver Spring, Maryland (“UT”), Accredo Health Group, Inc., a Delaware corporation having offices at 6272 Lee Vista Boulevard, Orlando FL, 32822 (“Accredo”), and Priority Healthcare Distribution, Inc., doing business as CuraScript SD Specialty Distribution, a Florida corporation with offices at 255 Technology Park, Lake Mary, Florida, 32746 (“SD”). SD and Accredo are collectively referred to herein as the “Distributor”.

 

WHEREAS, UT and Accredo entered into an Amended and Restated Distribution Agreement on February 21, 2011 (as amended from time to time, the “Agreement”) relating to the distribution of Remodulin® (treprostinil) Inhalation Solution; and

 

WHEREAS, the parties desire to amend the Agreement as provided herein.

 

NOW, THEREFORE, in consideration of the mutual agreements and covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, agree as follows:

 

1.              CuraScript, Inc. is no longer providing services under the Agreement and is, therefore, being removed as a party.

 

2.              AMENDMENT.  The Agreement is hereby amended by deleting Attachment C in its entirety, and amending Section 1.1(u) to read as follows:

 

“(u)                           “PAP Patient” shall mean any Included Patient who is enrolled in the Patient Assistance Program as established by  UT from time to time and operating in accordance with guidelines developed by UT.  UT shall provide DISTRIBUTOR with the eligibility criteria for this program, which UT may update from time to time in its discretion, upon written notice to DISTRIBUTOR.”

 

3.              COUNTERPARTS. This Amendment may be executed in any number of counterparts and via facsimile, email or other electronic form of transmission, and each of such counterparts shall for all purposes be deemed original, and all such counterparts shall together constitute one and the same instrument.

 

4.              EFFECT OF AMENDMENT.  Except as specifically amended hereby or by any previous amendments duly executed in accordance with the Agreement, all other terms and conditions of the Agreement remain in full force and effect. To the extent that any of the terms in the underlying agreement are inconsistent with the terms of this Amendment, the terms of this Amendment shall control.

 

[Signature page follows]

 

1

 

IN WITNESS WHEREOF, the parties hereto have caused this Second Amendment to be executed by their duly authorized representatives.

 

	
UNITED THERAPEUTICS
    	
 
    	
ACCREDO HEALTH GROUP, INC.
    
	
CORPORATION
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
/s/ Kevin Gray
    	
 
    	
/s/ Bill Martin
    
	
 
    	
 
    	
 
    
	
Name:
    	
Kevin Gray
    	
 
    	
Name:  
    	
Bill Martin
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Title:
    	
Senior Vice President, Strategic
    	
 
    	
Title:  
    	
VP
    
	
 
    	
Operations
    	
 
    	
 
    	
 
    
	
Date:
    	
1/3/2017
    	
 
    	
Date:  
    	
12/28/16
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
PRIORITY HEALTHCARE
    	
 
    	
 
    
	
DISTRIBUTION, INC.
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
/s/ Gayle C. Johnston
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Name: 
    	
Gayle C. Johnston
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
Title: 
    	
President
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
Date: 
    	
12/28/16Exhibit 10.50

 

Pursuant to 17 C.F.R §240.24b-2, confidential information (indicated as [***]) has been omitted and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission.

 

3RD AMENDMENT TO AMENDED AND RESTATED DISTRIBUTION AGREEMENT

(Remodulin®)

 

THIS 3RD AMENDMENT TO AMENDED AND RESTATED DISTRIBUTION AGREEMENT (this “Third Amendment”) is made and effective this 27th Day of December, 2016 (the “Third Amendment Effective Date”), by and among Accredo Health Group, Inc., a Delaware corporation having offices at 6272 Lee Vista Boulevard, Orlando FL, 32822, (“Accredo”), United Therapeutics Corporation, a Delaware corporation, having offices at 1040 Spring Street, Silver Spring, Maryland (“UT”), and Priority Healthcare Distribution, Inc., doing business as CuraScript SD Specialty Distribution, a Florida corporation with offices at 255 Technology Park, Lake Mary, Florida, 32746 (“SD”). SD and Accredo are collectively referred to herein as the “Distributor”.

 

WHEREAS, UT and Accredo are parties to that certain Amended and Restated Distribution Agreement dated February 21, 2011, as amended (the “Agreement”), which relates to the distribution of Remodulin® (treprostinil) Injection (“UT Product”);

 

WHEREAS, the Parties wish to amend the Agreement as provided herein;

 

WHEREAS, pursuant to Section 18.4 of the Agreement, the Agreement may be amended by the parties by a written instrument signed by a duly authorized representative of each of the Parties; and

 

WHEREAS, capitalized terms used but not defined herein shall have the meanings ascribed to them in the Agreement.

 

NOW THEREFORE, in consideration of the mutual agreements and covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto, intending to be legally bound, hereby agree as follows:

 

1.0                  Attachment A will be deleted in its entirety and replaced with the revised Attachment A, attached hereto..

 

(SIGNATURE PAGE TO FOLLOW)

 

1

 

Pursuant to 17 C.F.R §240.24b-2, confidential information (indicated as [***]) has been omitted and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission.

 

IN WITNESS WHEREOF, the parties hereto have caused this Third Amendment to be executed as of the Third Amendment Effective Date set forth above by their duly authorized representatives.

 

	
ACCREDO   HEALTH GROUP, INC.
    	
 
    	
UNITED   THERAPEUTICS CORPORATION
    
	
 
    	
 
    	
 
    
	
By:
    	
/s/ Bill Martin
    	
 
    	
By: 
    	
/s/ Kevin T. Gray
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Name:   
    	
Bill Martin
    	
 
    	
Name: 
    	
Kevin T. Gray
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Title:   
    	
VP
    	
 
    	
Title: 
    	
SVP, Strategic   Operations
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Date:   
    	
1/3/17
    	
 
    	
Date: 
    	
1/5/2017
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
PRIORITY   HEALTHCARE DISTRIBUTION, INC.
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
By: 
    	
/s/ Gayle C. Johnston
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
Name:   
    	
Gayle C. Johnston
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
Title:   
    	
President
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
Date:   
    	
12.30.16
    	
 
    	
 
    

 

2

 

Pursuant to 17 C.F.R §240.24b-2, confidential information (indicated as [***]) has been omitted and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission.

 

Attachment A

 

Prices

 

UT Product

 

	
UT   Product Name
    	
 
    	
NDC
    	
 
    	
Strength
    	
 
    	
Price
    	
 
    
	
Remodulin 1mg
    	
 
    	
66302-0101-01
    	
 
    	
1mg/20ml
    	
 
    	
$
    	
[***]
    	
 
    
	
Remodulin 2.5mg
    	
 
    	
66302-0102-01
    	
 
    	
2.5mg/20ml
    	
 
    	
$
    	
[***]
    	
 
    
	
Remodulin 5 mg
    	
 
    	
66302-0105-01
    	
 
    	
5mg/20ml
    	
 
    	
$
    	
[***]
    	
 
    
	
Remodulin 10 mg
    	
 
    	
66302-0110-01
    	
 
    	
10mg/20ml
    	
 
    	
$
    	
[***]
    	
 
    
	
Remodulin Diluent
    	
 
    	
(NDC 66302-150-50).
    	
 
    	
50 mL vial, carton of 1
    	
 
    	
$
    	
[***]
    	
 
    

 

UT shall notify the DISTRIBUTOR in writing of any change (and the amount of the change) in the Price of any respective UT Product during the term of this Agreement in the same time and manner as it notifies other similarly situated distributors.

 

UT shall provide DISTRIBUTOR with a current list of Remodulin prices to Discounted Entities, including FSS prices, Federal Ceiling Prices, and prices to section 340B entities, and shall promptly notify Distributor of any and all changes in such prices as well as the effective dates of such changes.

 

3Exhibit 10.55

 

Fourth Amendment to Distribution Agreement

(TYVASO®)

 

THIS FOURTH AMENDMENT TO DISTRIBUTION AGREEMENT (this “Third Amendment”) is made and effective November 1, 2016 (the “Fourth Amendment Effective Date”) by and among, United Therapeutics Corporation, a Delaware corporation having offices at 1040 Spring Street, Silver Spring, Maryland (“UT”), Accredo Health Group, Inc., a Delaware corporation having offices at 6272 Lee Vista Boulevard, Orlando FL, 32822 (“Accredo”), and Priority Healthcare Distribution, Inc., doing business as CuraScript SD Specialty Distribution, a Florida corporation with offices at 255 Technology Park, Lake Mary, Florida, 32746 (“SD”). SP, SD and Accredo are collectively referred to herein as the “Distributor”.

 

WHEREAS, UT and Accredo entered into a Distribution Agreement on August 17, 2009 (as amended from time to time, the “Agreement”) relating to the distribution of Tyvaso® (treprostinil) Inhalation Solution; and

 

WHEREAS, the parties desire to amend the Agreement as provided herein.

 

NOW, THEREFORE, in consideration of the mutual agreements and covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, agree as follows:

 

1.              CuraScript, Inc. is no longer providing services under the Agreement and is, therefore, being removed as a party.

 

2.              AMENDMENT.  The Agreement is hereby amended by deleting Attachment C in its entirety, and amending Section 1.1(r) to read as follows:

 

“(r)                              “PAP Patient” shall mean any Included Patient who is enrolled in the Patient Assistance Program as established by UT from time to time and operating in accordance with guidelines developed by UT.  UT shall provide DISTRIBUTOR with the eligibility criteria for this program, which UT may update from time to time in its discretion, upon written notice to DISTRIBUTOR.”

 

3.              COUNTERPARTS. This Amendment may be executed in any number of counterparts and via facsimile, email or other electronic form of transmission, and each of such counterparts shall for all purposes be deemed original, and all such counterparts shall together constitute one and the same instrument.

 

4.              EFFECT OF AMENDMENT.  Except as specifically amended hereby or by any previous amendments duly executed in accordance with the Agreement, all other terms and conditions of the Agreement remain in full force and effect. To the extent that any of the terms in the underlying agreement are inconsistent with the terms of this Amendment, the terms of this Amendment shall control.

 

[Signature page follows]

 

1

 

IN WITNESS WHEREOF, the parties hereto have caused this Fourth Amendment to be executed by their duly authorized representatives.

 

	
UNITED   THERAPEUTICS
    	
 
    	
ACCREDO   HEALTH GROUP, INC.
    
	
CORPORATION
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
/s/ Kevin T. Gray
    	
 
    	
/s/ Bill Martin
    
	
 
    	
 
    	
 
    
	
Name:   Kevin Gray
    	
 
    	
Name: Bill Martin
    
	
 
    	
 
    	
 
    
	
Title:
    	
 Senior Vice President, Strategic
    	
 
    	
Title: VP
    
	
 
    	
Operations
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Date: 1/3/2017
    	
 
    	
Date: 12/28/16
    
	
 
    	
 
    	
 
    
	
PRIORITY   HEALTHCARE DISTRIBUTION, INC.
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Name:   /s/ Gayle C. Johnston
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Title: President
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Date: 12/28/16

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00267-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00267-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00267-of-00352.parquet"}]]